Brief: AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement Of Oral An2-502998 To Phase 2 Study For Chronic Chagas Disease
04/06/2026 12:08
BRIEF-AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement Of Oral An2-502998 To Phase 2 Study For Chronic Chagas Disease June 4 (Reuters) - AN2 Therapeutics Inc ANTX.O:
AN2 THERAPEUTICS REPORTS POSITIVE ENABLING DATA SUPPORTING ADVANCEMENT OF ORAL AN2-502998 TO PHASE 2 STUDY FOR CHRONIC CHAGAS DISEASE
AN2 THERAPEUTICS - PHASE 1 STUDY SHOWS FAVORABLE SAFETY AND NO DOSE-LIMITING TOXICITIES FOR AN2-502998
Source text: ID:nBw7vkpW7a
Further company coverage: ANTX.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview